Abstract:INTRODUCTION AND OBJECTIVES: Sphingosine kinase 1 (SphK1) is the major source of the bioactive lipid and GPCR (G-proteincoupled receptor) agonist sphingosine 1-phosphate (S1P). Numerous studies have documented that SphK1-S1P signalling has multiple functions in tumorigenesis. The present study was conducted to investigate the expression of SphK1-S1P signalling and its prognostic significance in renal cell carcinoma (RCC). Meanwhile, we set out to SphK1 as a novel molecular target in RCC and examine its role in tumor cell growth and sunitinib resistance in vitro and in vivo. METHODS: In this study, SphK1 expression levels as well as clinicopathological significance were evaluated in RCC cell lines and primary RCC clinical specimens by immunohistochemistry, immunofluorescence assay, qRT-PCR and western blot. We assessed the levels of S1P and Sph in tumor tissues by HPLC analysis and in the plasma of RCC patients and healthy controls by LC-MS/MS analysis. In vitro and in vivo knockdown or overexpression of SphK1 in RCC cell lines was used to determine its effecton tumor growth, cellular proliferation, colony formation, migration, invasion, and apoptosis. We conducted a phosphoprotein antibody array to identify ectopic phosphorylated proteins induced in 786-O cells with/without SphK1 expression vector. In addition,we further evaluated the effect of SphK1 antagonist fingolimod (FTY720) in RCC in vitro and in vivo, as a single agent or in combination with sunitinib, and attempted to explore its anticarcinogenic mechanisms. RESULTS: We identify upregulation of SphK1 significantly associated with poor prognosis of RCC patients, which contributing to renal proliferation, colony formation, migration and survival. Suppression of SphK1 activity either by shRNA or pharmacologic inhibitior FTY720 suppresses cell growth in vitro and in vivo. A comprehensive phosphoprotein antibody array reveals that SphK1 overexpression promoted RCC progression by regulating the Akt/mTOR pathway. SphK1 could act as a canonical regulator of hypoxia-inducible HIF-1&agr; and HIF-2&agr; in RCC cells. Moreover, stem-like phenotype due to sunitinib administration via oncogenic activation of SphK1 could be ameliorated by SphK1 shRNA and FTY720. FTY720 administration enhanced tumor growth inhibition effect of sunitinib treatment on RCC cells in vitro and in vivo. CONCLUSIONS: Our results unraveled that increased SphK1 kinase activation defines an important mechanism for maintaining stemlike phenotype and sunitinib resistance, therefore contributes to tumour development and represents therapeutic targets for RCC. Source of Funding: none

Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma

Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.

Sunitinib Impairs the Proliferation and Function of Human Peripheral T Cell and Prevents T-cell-mediated Immune Response in Mice.

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments

MP16-13 SETD2-MEDIATED LOSS OF MIR-339 PROMOTES TUMOR PD-L1 EXPRESSION AND ATTENUATES ANTITUMOR IMMUNITY IN RENAL CELL CARCINOMA

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

Reversing Sunitinib Resistance Facilitated by ITGA1 Through the PI3K/Akt/Bcl-2 Pathway Using Nano Co-Delivery System in Renal Cell Carcinoma

Key sunitinib-related biomarkers for renal cell carcinoma

Inhibition of Renalase Expression and Signaling Has Antitumor Activity in Pancreatic Cancer

A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1

Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model

Expression of programmed cell death protein-ligand 1 in metastatic renal cell carcinoma and its relationship to prognosis

MP21-17 SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA

Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

LncRNA HOTAIR induces sunitinib resistance in renal cancer by acting as a competing endogenous RNA to regulate autophagy of renal cells

Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

Checkpoint Molecule PD-1-assisted CD8+ T Lymphocyte Count in Tumor Microenvironment Predicts Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.